DHX9-IN-9
DHX9-IN-9 (509) is a RNA helicase DHX9 inhibitor, with an EC50 of 0.0177 μM in DHX9 cellular target engagement. Used in cancer research[1].
Product Specifications
CAS Number
2973400-46-1
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dhx9-in-9.html
Concentration
10mM
Purity
99.79
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC(C2=NC=C(N3CC(C3)F)C=N2)=C(C)S1)NC4=CC(Cl)=CC(NS(=O)(CC)=O)=C4
Molecular Formula
C21H21ClFN5O3S2
Molecular Weight
510.00
References & Citations
[1]Matthew H, et al. Inhibitors of rna helicase dhx9 and uses thereof. Patent WO2023154519.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940630-100 1x 100 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470630-500 1x 500 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680226-500 1x 500 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740965-500 1x 500 µL
MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details